Trial · NCT07020923
Monthly Dosing of Atacicept in IgAN
NCT07020923, Phase 2, Active not recruiting, Vera Therapeutics, Inc.
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Monthly Dosing of Atacicept in IgAN. Trials, record NCT07020923. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07020923
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Monthly Dosing of Atacicept in IgAN
- NCT number
- NCT07020923
- Status
- Active not recruiting
- Phases
- Phase 2
- Enrollment
- 90 participants, estimated
- Lead sponsor
- Vera Therapeutics, Inc.
- Conditions
- IgA Nephropathy (IgAN), Berger Disease
- Interventions
- Atacicept
- First posted
- 2025-06-13
- Last updated
- 2026-04-13
Source ClinicalTrials.gov
Registered outcomes6
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Evaluate the effect of atacicept on Gd-IgA1 in patients with IgAN | Up to 24 weeks | Gd-IgA1 levels through Week 24 |
| Secondary | To evaluate the safety and tolerability of atacicept at different dosing regimensT | Baseline until end of study up to Week 24 | Incidence of treatment emergent reported Adverse Events (AE) |
| Secondary | To evaluate the effect of atacicept on serum immunoglobulins (IgA) | 24 Weeks | IgA levels through Week 24 |
| Secondary | To evaluate the effect of atacicept on serum immunoglobulins (IgG) | 24 Weeks | IgG levels through Week 24 |
| Secondary | To evaluate the effect of atacicept on serum immunoglobulins (IgM) | 24 Weeks | IgM levels through Week 24 |
| Secondary | To evaluate serum PK of atacicept | Baseline until end of study up to Week 24 | Serum concentration of atacicept |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07020923
GET https://conductscience.org/api/trials/v1/NCT07020923/registered